{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:19:47Z","timestamp":1791069587096,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1124\/mol.109.058057","type":"journal-article","created":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T01:11:52Z","timestamp":1246497112000},"page":"710-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment"],"prefix":"10.1016","volume":"76","author":[{"given":"Xi-Ping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem N.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Rogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie J.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetana","family":"Revankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Robers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.109.058057_bib1","doi-asserted-by":"crossref","unstructured":"Berger M, Gray JA and Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355\u2013366.","DOI":"10.1146\/annurev.med.60.042307.110802"},{"key":"10.1124\/mol.109.058057_bib2","doi-asserted-by":"crossref","unstructured":"Bourdon DM, Wing MR, Edwards EB, Sondek J and Harden TK (2006) Quantification of isozyme-specific activation of phospholipase C-beta2 by Rac GTPases and phospholipase C-epsilon by Rho GTPases in an intact cell assay system. Methods Enzymol 406:489\u2013499.","DOI":"10.1016\/S0076-6879(06)06037-X"},{"key":"10.1124\/mol.109.058057_bib3","doi-asserted-by":"crossref","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254.","DOI":"10.1006\/abio.1976.9999"},{"key":"10.1124\/mol.109.058057_bib4","doi-asserted-by":"crossref","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD and Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581\u2013588.","DOI":"10.1056\/NEJM199708283370901"},{"key":"10.1124\/mol.109.058057_bib5","doi-asserted-by":"crossref","unstructured":"Droogmans S, Cosyns B, D\u2019haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, et al. (2007) Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100:1442\u20131445.","DOI":"10.1016\/j.amjcard.2007.06.045"},{"key":"10.1124\/mol.109.058057_bib6","doi-asserted-by":"crossref","unstructured":"Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD and Slocum N (2008) 5-Hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60:253\u2013262.","DOI":"10.1016\/j.etp.2008.03.005"},{"key":"10.1124\/mol.109.058057_bib7","doi-asserted-by":"crossref","unstructured":"Elangbam CS, Lightfoot RM, Yoon LW, Creech DR, Geske RS, Crumbley CW, Gates LD and Wall HG (2005) 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53:671\u2013677.","DOI":"10.1369\/jhc.4A6500.2005"},{"key":"10.1124\/mol.109.058057_bib8","doi-asserted-by":"crossref","unstructured":"Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75\u201381.","DOI":"10.1016\/S0026-895X(24)26444-0"},{"key":"10.1124\/mol.109.058057_bib9","doi-asserted-by":"crossref","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, et al. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656\u2013662.","DOI":"10.1002\/mds.20201"},{"key":"10.1124\/mol.109.058057_bib10","doi-asserted-by":"crossref","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB and Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology 33:2303\u20132312.","DOI":"10.1038\/sj.npp.1301646"},{"key":"10.1124\/mol.109.058057_bib11","doi-asserted-by":"crossref","unstructured":"Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM and Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280\u20131286.","DOI":"10.4065\/77.12.1280"},{"key":"10.1124\/mol.109.058057_bib12","doi-asserted-by":"crossref","unstructured":"Regard JB, Sato IT and Coughlin SR (2008) Anatomical profiling of G protein-coupled receptor expression. Cell 135:561\u2013571.","DOI":"10.1016\/j.cell.2008.08.040"},{"key":"10.1124\/mol.109.058057_bib13","doi-asserted-by":"crossref","unstructured":"Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6\u20139.","DOI":"10.1056\/NEJMp068265"},{"key":"10.1124\/mol.109.058057_bib14","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836\u20132841.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"10.1124\/mol.109.058057_bib15","doi-asserted-by":"crossref","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W and Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338.","DOI":"10.1056\/NEJMoa062222"},{"key":"10.1124\/mol.109.058057_bib16","doi-asserted-by":"crossref","unstructured":"Setola V, Dukat M, Glennon RA and Roth BL (2005) Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 68:20\u201333.","DOI":"10.1124\/mol.104.009266"},{"key":"10.1124\/mol.109.058057_bib17","doi-asserted-by":"crossref","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB and Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223\u20131229.","DOI":"10.1124\/mol.63.6.1223"},{"key":"10.1124\/mol.109.058057_bib18","doi-asserted-by":"crossref","unstructured":"Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hufeisen SJ, Leahy P, Br\u00fcning JC and Roth BL (2006) p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. Proc Natl Acad Sci U S A 103:4717\u20134722.","DOI":"10.1073\/pnas.0600585103"},{"key":"10.1124\/mol.109.058057_bib19","doi-asserted-by":"crossref","unstructured":"Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM and Shanahan WR APD356\u2013004 Study Group (2009) Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 17:494\u2013503.","DOI":"10.1038\/oby.2008.537"},{"key":"10.1124\/mol.109.058057_bib20","doi-asserted-by":"crossref","unstructured":"Steffee CH, Singh HK and Chitwood WR (1999) Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8:245\u2013253.","DOI":"10.1016\/S1054-8807(99)00019-8"},{"key":"10.1124\/mol.109.058057_bib21","doi-asserted-by":"crossref","unstructured":"Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, et al. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577\u2013587.","DOI":"10.1124\/jpet.107.133348"},{"key":"10.1124\/mol.109.058057_bib22","doi-asserted-by":"crossref","unstructured":"Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1\u201313.","DOI":"10.1124\/jpet.106.104463"},{"key":"10.1124\/mol.109.058057_bib23","doi-asserted-by":"crossref","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S and Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346.","DOI":"10.1056\/NEJMoa054830"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2402039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2402039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.109.058057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:39:37Z","timestamp":1739957977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2402039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0026895X2402039X"],"URL":"https:\/\/doi.org\/10.1124\/mol.109.058057","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.109.058057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}